Mineralocorticoid and renal receptor binding activity of 21-deoxy aldosterone

Hideo Koshida, Isamu Miyamori, Ryuichiro Soma, Takao Matsubara, Masatoshi Ikeda, Ryoyu Takeda, Shinichi Nakamura, Fumiyuki Kiuchi, Yoshisuke Tsuda

研究成果: Article査読

10 被引用数 (Scopus)


Since several aldosterone metabolites are known to be active, we have assessed the mineralocorticoid biological and renal receptor binding activities of the aldosterone metabolites, 21-deoxyaldosterone (21-deoxy-Aldo), 21-deoxytetrahy-droaldosterone (21-deoxy-THAldo), and 3α, 5 β-tetrahydroaldos-terone (THAldo). We synthesized these steroids by bioreduction of aldosterone with intestinal bacteria. Mineralocorticoid agonist activity of 21-deoxy-Aldo, 21-deoxy-THAldo and THAldo, determined by bioassay using adrenalectomized rats, was 1-5%, less than 0.01%, and 0.1-0.5% that of aldosterone, respectively. 21-De.oxy-Aldo showed no antagonist activity. The relative affinity in competing with [3H] aldosterone for binding to mineralocorticoid receptors in adrenalectomized rat kidney cytosols was 94%, less than 0.01%, and less than 0.01% that of aldosterone. The relative binding affinity for rat renal glucocorticoid receptors was 23%, less than 0.01%, and less than 0.01% that of dexamethasone, and for corticosteroid-binding globulin 17%, less than 0.01%, and less than 0.01% that of Cortisol. These results show that the naturally occurring steroid, 21-deoxy-Aldo, possesses mineralocorticoid agonist activity which is equivalent to that of 11-deoxycorticosterone, and has substantial affinity for rat renal mineralocorticoid and glucocorticoid receptors. The results also implicate the pathophysiological role of 21-deoxy-Aldo as a potential mineralocorticoid in 21-hydroxylase defi-ciency, where urinary excretion of this steroid is invariably elevated.

出版ステータスPublished - 1990 3月

ASJC Scopus subject areas

  • 内分泌学


「Mineralocorticoid and renal receptor binding activity of 21-deoxy aldosterone」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。